This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

For investors still cringing at their IRAs, 401(k)s or taxable mutual funds and exchange-traded funds, are you ready to take a chance on the companies that have brought you so many unhappy returns?

The regionals may not have as much recognition as the mammoth securities firms, but they won't be receiving as many unwanted headlines either.

If Pfizer's looking for the next Lipitor, it probably hasn't found it with the acquisition of Wyeth.

Allergan, Mentor and Medicis have struggled in the past year, but if the economy improves, share prices could, too.

For Abbott, Diversity Remains Paramount

08/21/08 - 01:06 PM EDT

When it comes to investing in big pharmaceutical stocks, it's hard to top this company, especially as its peers continue to suffer.

Legal Questions Still Dogging Wyeth

07/21/08 - 12:37 PM EDT

The company continues to wrestle with the dilemma surrounding the drugs Premarin, Prempro and Premphase. Plaintiffs' lawyers have filed approximately 5,400 lawsuits.

In the past five years, its stock has more than tripled, easily outperforming the S&P 500 and the Amex Index of large drug stocks. Is anyone paying attention?

Shares of most major generic-drugmakers have traded below the S&P 500 for the 12 months ended May 23, and that index was off nearly 10%.

Need Defense? Think Medical Supplies

04/11/08 - 06:44 AM EDT

Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.

The companies that supply the tools needed for pharma research and development often profit no matter the success of a drug trial.

Page 1 of 147
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs